in

Hims & Hers CEO on why weight loss drugs haven’t hit the platform yet

Telehealth company Hims & Hers has been an outlier among public digital health companies in that it’s invoking optimism among Wall Street investors.

While other public digital health companies have yet to climb out of their stock price free fall, Hims & Hers is up 244% from one year ago. The direct-to-consumer company, which offers telehealth care and medical prescriptions for sexual health, hair loss, mental health and dermatology, has…

Read the full post

Written by Editor

Richemont Wins Support of Proxy Adviser Against Activist Investor Bluebell

Richemont Shoots Down Reports of LVMH Takeover Interest

City and beach retreat: How to get the ‘best of both worlds’ in Portugal